Invasive Pneumococcal Disease Prevention in Adults
Invasive Pneumococcal Disease in Alaskan Adults Experiencing Homelessness
Low uptake of pneumococcal conjugate vaccines among adults contributes to an increase in invasive pneumococcal disease, especially in those experiencing homelessness, say the Alaska-based authors of a new study.
When Children Get the Pneumococcal Vaccine, Adults Benefit, Too
New information from Germany confirms that vaccinating children for pneumococcal disease has a protective effect on adults. But don’t count on the kids—adults need their own vaccinations, as well.
Pneumococcal Carriage in the COVID-19 Era
New research found that despite COVID-19-era precautions—including masking and social distancing—rates of pneumococcal carriage among older adults were similar to those reported in this population before the pandemic.
Determining the Best Time to Vaccinate Against Invasive Pneumococcal Disease
In a study of 4 countries, an international team of experts set out recently to determine the optimal age for older adults to receive a single-dose pneumococcal vaccine.
Vaccination Against IPD: A One-Two Protective Punch for Patients with Sickle Cell Disease
Invasive pneumococcal disease is a deadly complication of sickle cell disease (SCD). A new report, however, suggests that immunization with PCV13 plus PPSV23 produces a better humoral immune response than PPSV23 alone in adults with SCD.
.jpg)
PCV13 and Pneumonia Hospitalization in Older Adults
A recent study explored whether 13-valent pneumococcal conjugate vaccine (PCV13) reduces pneumonia hospitalizations among older adults with a high prevalence of underlying conditions.
Can This One Deadly Disease (Pneumonia) Trigger Another (MI)?
Do patients who get pneumonia increase their risk of a heart attack? And if so, by how much? Do only older people need to be worried about this? These questions were at the focus of a case series study that used data spanning a 16-year period.
Invasive Pneumococcal Disease: Which Workplace Exposures Raise the Risk?
That was the question asked by Swedish investigators who examined the effect of occupational exposures—including their nature and work location—on the risk of transmission of invasive pneumococcal disease.
Do Adults Benefit When Kids Get Pneumococcal Conjugate Vaccines?
The answer appears to be "yes." A sharp decrease in rates of pneumococcal pneumonia caused by pneumococcal conjugate vaccine serotypes was observed in men and women, according to these recent findings from a Japanese study.
PCV13 Is Shifting Trends in Invasive Pneumococcal Disease
With data from patients in Olmstead County, Minnesota, researchers at Mayo Clinic recently took a close look at the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13). Here’s what they found.